NKIRAS1: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

Target Name: NKIRAS1

NCBI ID: G28512

NKIRAS1

NKIRAS1: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

NKIRAS1 (KappaB-Ras1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a significant amount of research in the field of Oncology.

NKIRAS1 is a RNA molecule that is derived from the KappaB gene, which is a well-known gene that is involved in cell signaling and survival. The KappaB gene is a transcription factor, which means it regulates the transcription of other genes. NKIRAS1 is a non-coding RNA molecule that is generated from the KappaB gene and has been shown to have a variety of functions in cell signaling pathways.

One of the most significant functions of NKIRAS1 is its ability to regulate cell signaling pathways. NKIRAS1 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo and die. NKIRAS1 has been shown to induce cell apoptosis by activating the Bax gene, which is a known transcriptional regulator that is involved in cell death.

In addition to its role in cell apoptosis, NKIRAS1 has also been shown to play a role in the regulation of cell growth and differentiation. NKIRAS1 has been shown to regulate the translation of the growth factor receptor GLI1, which is involved in cell growth and differentiation..

NKIRAS1 has also been shown to have a variety of potential drug targets. One of the most promising targets is the protein p18, which is a known protein that is involved in cell cycle progression and has been shown to be a potential drug target for various diseases , including cancer. NKIRAS1 has been shown to interact with p18 and can inhibit the activity of p18, which suggests that NKIRAS1 may be a useful drug target for cancer treatment.

Another potential drug target for NKIRAS1 is the protein p53, which is a well-known protein that is involved in cell signaling and has been shown to play a role in the regulation of cell apoptosis. NKIRAS1 has been shown to interact with p53 and can inhibit the activity of p53, which suggests that NKIRAS1 may be a useful drug target for cancer treatment.

In addition to its potential drug targets, NKIRAS1 has also been shown to have a variety of potential biomarkers. For example, NKIRAS1 has been shown to have a potential diagnostic impact in the diagnosis of pancreatic cancer, by detecting the expression of NKIRAS1 in pancreatic cancer cells. Additionally, NKIRAS1 has been shown to have a potential diagnostic impact in the diagnosis of colorectal cancer, by detecting the expression of NKIRAS1 in colorectal cancer cells.

Overall, NKIRAS1 is a non-coding RNA molecule that has a variety of functions in cell signaling pathways. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a significant amount of research in the field of Oncology. Further research is needed to fully understand the role of NKIRAS1 in cell signaling pathways and its potential as a drug or biomarker.

Protein Name: NFKB Inhibitor Interacting Ras Like 1

Functions: Atypical Ras-like protein that acts as a potent regulator of NF-kappa-B activity by preventing the degradation of NF-kappa-B inhibitor beta (NFKBIB) by most signals, explaining why NFKBIB is more resistant to degradation. May act by blocking phosphorylation of NFKBIB and mediating cytoplasmic retention of p65/RELA NF-kappa-B subunit. It is unclear whether it acts as a GTPase. Both GTP- and GDP-bound forms block phosphorylation of NFKBIB

The "NKIRAS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKIRAS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets